Callista Indus. (539335)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• At ₹8.33, the stock is at the bottom of its 52-week range, so much of the collapse from ₹225.95 may already be discounted by the market.
• The latest quarterly net loss rounds to ₹0 Cr, suggesting the reported operating loss is not a large absolute cash drain.
• No dividend is paid, so there is no cash outflow for shareholder returns during a potential reset.
• It is a listed entity, which gives it speculative restructuring or reverse-merger optionality—though that is not a fundamental moat.

Concerns

• Latest quarter shows sales of ₹0 Cr and sales growth of 0.00%; a distributor with no revenue is not an operating business.
• Profit growth is -1500.00% and Piotroski F-Score is 2/9, indicating severe financial deterioration and little balance-sheet resilience.
• ROCE is -104.13%, showing capital is being destroyed, while the headline ROE of 743.99% is misleading without book value data.
• Market cap is stated as ₹0 Cr, book value is N/A, and promoter holding is N/A; there is insufficient data to compute intrinsic value or margin of safety.

AI Analysis

Callista Indus. is exactly the kind of situation that demands discipline. On the surface, an ROE of 743.99% might catch attention, but I have learned to look beneath the wrapper. With ROCE at -104.13% and latest quarter sales of ₹0 Cr, that ROE is not economic success; it is a product of a tiny equity base and leverage. The stock has collapsed from ₹225.95 to ₹8.33 in its 52-week range, and the stated market capitalisation is effectively ₹0 Cr. When Mr. Market marks a company down by roughly 96%, he is telling me something. Profit growth at -1,500% and a Piotroski F-Score of 2/9 reinforce deteriorating fundamentals. There is no dividend, no sales growth, and no book value disclosed. As a distributor, the absence of revenue is existential—a trading company with nothing to trade is a shell, not a business. I cannot calculate any margin of safety because I do not have asset values or liabilities; I would be buying blind. Graham taught me that price is what you pay, value is what you get. Here, the price has fallen, but the value is unknown. This is not a wonderful company at a fair price; it is a questionable company at an uncertain price. I would put Callista in the 'too hard' pile and wait for a balance sheet, a revenue plan, and evidence of a genuine turnaround. Speculators may hope for a re-rating from a reverse merger or restructuring, but as an investor, hope is not a strategy.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer